Methylation analysis of the O6-methylguanine DNA methyltransferase (MGMT) gene promoter from glioma tumor tissue is medically necessary for individuals who meet the following criteria:
They have a tumor type consistent with high-grade malignant glioma (eg, glioblastoma multiforme, anaplastic astrocytoma); and
Candidate for temozolomide therapy or radiotherapy; and
Methylation results will be used to direct their therapy choices.
MGMT promoter methylation analysis is investigational in situations that do not meet the above criteria.
